Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 known ✓ | P04062 | 1/20 | 0.35 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.32 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL1131805 | 1.00 | MAPT (0.57) | MAPTTSHRCYP2C9PDE4AGBA1 | |
| Tartaric Acid SCHEMBL30104959 | 1.00 | MAPT (0.57) | MAPTTSHRCYP2C9PDE4AGBA1 | |
| Lactic Acid SCHEMBL1131790 | 0.86 | MAPT (0.57) | MAPTOR51E2TP53CHRNB2CHRNA4 | |
| Dimethylaminoethanol SCHEMBL1131465 | 0.82 | MAPT (0.75) | MAPTTSHRCHRNB2CHRNA4CHRM2 | |
| Dimethylaminoethanol SCHEMBL1131226 | 0.82 | MAPT (0.75) | MAPTTSHRCHRNB2CHRNA4CHRM2 | |
| Dimethylaminoethanol SCHEMBL13730571 | 0.80 | MAPT (0.50) | MAPTOR51E2 | |
| Cadaverine Tartrate SCHEMBL8339185 | 0.80 | TSHR (0.53) | MAPTTSHRCYP2C9PDE4AGBA1 | |
| Cadaverine Tartrate SCHEMBL5874849 | 0.80 | TSHR (0.53) | MAPTTSHRCYP2C9PDE4AGBA1 | |
| Cadaverine Tartrate SCHEMBL8830362 | 0.80 | TSHR (0.53) | MAPTTSHRCYP2C9PDE4AGBA1 | |
| Dimethylaminoethanol SCHEMBL358310 | 0.79 | MAPT (0.71) | MAPTTSHRCHRNB2CHRNA4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260114468-A1 | PACKAGED FOOD MIXTURE | CPRG, LLC (US) | 2026-04-30 | — | — | US | claimed |
| US-20250367206-A1 | 1-METHYLXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2025-12-04 | — | — | US | claimed |
| US-12390470-B2 | 1-methylxanthine-based bioactive composition and method of use thereof | Ingenious Ingredients, LP (US) | 2025-08-19 | — | — | US | claimed |
| CN-118632697-A | Bioactive compositions and methods of use thereof | 南京纽邦生物科技有限公司 | 2024-09-10 | — | — | CN | claimed |
| EP-4376846-A1 | BIOACTIVE COMPOSITIONS AND METHODS OF USE THEREOF | PX ING, LLC (US) | 2024-06-05 | — | — | EP | claimed |
| CN-117979971-A | Bioactive compositions based on 1-methylxanthines and methods of use thereof | 独创成分有限合伙公司 | 2024-05-03 | — | — | CN | claimed |
| EP-3651770-B1 | THEACRINE-BASED SUPPLEMENT AND METHOD OF USE THEREOF IN A SYNERGISTIC COMBINATION WITH CAFFEINE | ORTHO NUTRA LLC (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2023064511-A9 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2023064511-A1 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230115966-A1 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | PX ING, LLC | 2023-04-13 | — | — | US | claimed |
| EP-4093296-A1 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2022-11-30 | — | — | EP | claimed |
| US-20220331328-A1 | 1-METHYLXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP | 2022-10-20 | — | — | US | claimed |
| WO-2014039011-A1 | METHODS TO INHIBIT INTRACELLULAR GROWTH OF BACTERIA AND TO TREAT BACTERIA-MEDIATED DISEASES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-03-13 | — | — | WO | claimed |
| EP-2155261-A1 | SENSORY FEEDBACK-BASED METHOD FOR DETERMINING THE BIOAVAILABILITY OF ORALLY ADMINISTERED DIETARY SUPPLEMENTS | Northern Innovations And Formulations Corp. (CA) | 2010-02-24 | — | — | EP | claimed |
| WO-2008138099-A1 | SENSORY FEEDBACK-BASED METHOD FOR DETERMINING THE BIOAVAILABILITY OF ORALLY ADMINISTERED DIETARY SUPPLEMENTS | MULTI FORMULATIONS LTD. (CA) | 2008-11-20 | — | — | WO | claimed |
| US-20080276732-A1 | INDICATOR FOR ORALLY ADMINISTERED COMPOSITIONS | MULTI FORMULATIONS LTD. (CA) | 2008-11-13 | — | — | US | claimed |
| US-20080213401-A1 | NUTRITIONAL SUPPLEMENTS FOR HEALTHY MEMORY AND MENTAL FUNCTION | PROGRESSIVE LABORATORIES, INC. | 2008-09-04 | — | — | US | claimed |
| US-20070185330-A1 | Liquids | THE UNIVERSITY OF YORK (GB) | 2007-08-09 | — | — | US | claimed |
| WO-2004100896-A2 | ANTI-AGING NUTRITIONAL SUPPLEMENT | GIAMPAPA VINCENT C (US) | 2004-11-25 | — | — | WO | claimed |
| US-20040001817-A1 | Anti-aging nutritional supplement | KRONOGEN SCIENCES INC. | 2004-01-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260114468-A1 | PACKAGED FOOD MIXTURE | SPTAN1, SET, ATXN2L | GBA1 4283/4885CHRM2 4062/4885CHRM4 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.